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The Epstein-Barr virus (EBV) encoded LMP1 protein is expressed in EBV-positive 
Hodgkin’s disease and is a potential target for cytotoxic T-lymphocytes (CTL) therapy.  
However, the LMP1-specific CTL frequency is low and so far the generation of LMP1-
specific CTL has required T-cell cloning.  The toxicity of LMP1 has prevented the use of 
dendritic cells (DC) for CTL stimulation and we reasoned that an inactive, non-toxic 
LMP1 mutant (￿LMP1) could be expressed in DC and would enable the activation and 
expansion of polyclonal LMP1-specific CTL.  Recombinant adenoviral vectors 
expressing LMP1 or ￿LMP1 were tested for their ability to transduce DC.  LMP1 
expression was toxic within 48 hours whereas high levels of ￿LMP1 expression were 
achieved with minimal toxicity.  ￿LMP1 expressing DC were able to reactivate and 
expand LMP1-specific CTL from three healthy EBV-seropositive donors.  LMP1-specific 
T cells were detected by IFN-￿ ELISPOT assays using the HLA-A2 restricted LMP1 
peptide, YLQQNWWTL (YLQ).  YLQ-specific T cells were undetectable (<0.001%) in 
donor PBMC, however after stimulation the frequency increased to 0.5-3.8%.  Lysis of 
autologous target cells by CTL was dependent on the level of LMP1 expression.  In 
contrast the frequency of YLQ-specific CTL in EBV-specific CTL reactivated and 
expanded using lymphoblastoid cell lines was low and no LMP1-specific cytotoxic 
activity was observed.  Thus ￿LMP1 expression in DC is non-toxic and enables the 
generation of LMP1-specific CTL for future adoptive immunotherapy protocols for 
patients with LMP1-positive malignancies such as EBV-positive Hodgkin’s disease.  
Targeting LMP1 in these malignancies may improve the efficacy of current adoptive 
immunotherapy approaches.  
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Immunotherapy with cytotoxic T cells (CTL) is increasingly used to treat malignancies 
and viral infections
1; 2. For example, polyclonal EBV-specific CTL have been used for 
the prevention and treatment of post transplant EBV-associated lymphoma (PTLD)
3.  
EBV-specific CTL persisted long-term, reconstituted immunity against EBV, and 
produced anti-viral and anti-lymphoma effects.  We have also used EBV-specific CTL to 
treat 13 patients with EBV-positive Hodgkin’s disease and while the results have been 
promising, no patient with bulky disease has been cured
1; 4.  One explanation for this 
failure is that current methods of EBV-specific CTL generation produce CTL lines, that 
are dominated by clones reactive to EBV proteins not expressed in the malignant Reed-
Sternberg cells (H-RS cells) of EBV-positive Hodgkin’s disease
5.  Only a limited number 
of EBV derived antigens (EBNA1, BARF0, LMP1 and LMP2) are present in H-RS cells
6; 
7 and the immunodominat response of CTL lines is against EBNAs 3A, B and C which 
are not expressed by the tumor cells.  Of the EBV proteins expressed in H-RS cells only 
LMP2 and LMP1 are potential targets for CD8 positive T cells, since EBNA 1 is mainly 
presented on MHC class II molecules
8 and the level of BARF0 expression might be too 
low for CTL recognition
9.  Our group and others have recently reported the generation 
of LMP2-specific CTL
10-12, however for future clinical protocols it is desirable to generate 
CTL against more than one tumor associated antigens expressed in H-RS cells to 
reduce the risk of T-cell escape mutants
13-15 and to ensure that good CTL epitopes are 
available regardless of the patient’s HLA type. LMP1-specific CTL are rarely detected in 
healthy EBV-seropositive individuals
5 and reactivation of LMP1-specific CTL lines has 
been difficult, in part because LMP1 is toxic when expressed at high levels
16.  It has 
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epitopes
17 or antigen presenting cells infected with a recombinant vaccinia virus 
overexpressing LMP1
18.  The generated T-cell clones were able to lyse targets 
expressing LMP1 and autologous LCL providing the rational for the development of an 
adoptive immunotherapy for EBV-associated malignancies like Hodgkin’s disease or 
nasopharyngeal carcinoma.  However the adoptive immunotherapy with T-cell clones is 
not ideal, since the generation of T-cell clones is labor intensive limiting its application 
for adoptive immunotherapy protocols.  Moreover, T-cell clones 1) do not persist in 
patients without the presence of specific CD4 positive T helper cells
19 and 2) carry the 
inherent risk that they may be evaded by epitope escape mutants
13-15. 
Thus, we have taken a different approach and generated polyclonal LMP1-specific CTL 
lines by stimulating PBMC with DC expressing a functionally inactive, non-toxic LMP1 
mutant.  We used a 43 aminoacid N-terminal deletion mutant, which renders the 
molecule inactive and non-toxic
20.  90% of the molecule remains intact for antigen 
processing and the two previously identified HLA-A2 restricted epitopes remain intact
17.  
Here, we show that high levels of LMP1 expression can be achieved in human dendritic 
cells (DC) with little toxicity using a recombinant ￿LMP1 adenovirus (Ad_￿LMP1).  
Moreover, stimulation of PBMC with DC expressing ￿LMP1 led to an at least 500 -
3,800 x fold increase in the frequency of LMP1-specific CTL, which were able to lyse 
wildtype LMP1-expressing target cells. 
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Blood donors and cell lines 
The study was performed on an IRB approved protocol and informed consent was 
obtained from all donors.  Autologous and mismatched lymphoblastoid cell lines (LCL) 
were established as previously described
21.  Primary autologous skin fibroblasts were 
isolated by punch biopsies taken from the volar surface of the forearm. LCL and 
fibroblasts were maintained in RPMI 1640 (HyClone, Logan, UT) containing 2mM 
GlutaMAX
TM-I (Invitrogen, Carlsbad, CA) and 10% fetal calf serum (FCS; HyClone, 
Logan, UT).  
HLA type of cell lines
The HLA class I type was for donor A HLA-A2, -B27 and -B51, donor B HLA-A2, -A3, -
B35 and -B57 and donor C HLA-A2, -A3, -B7 and -B44.  Mismatched LCL for donor A 
were HLA-A1, -A31, -B7 and -B8, for donor B HLA-A24, -A33, -B7, and -B65 and for 
donor C HLA-A11, -A31, -B8 and -B38.
Construction of recombinant adenoviruses 
The plasmid pSG5-LMP1 was provided by Bill Sugden, University of Wisconsin, 
Madison, WI.  LMP1 was subcloned into pEGFP-C1 (BD Biosciences, Palo Alto, Ca) 
using BamH I and Bgl II sites. The Sma I/Xba I LMP1 fragment of pEGFP-C1-LMP1 
was inserted into the Xba I and  Not  I (Klenow filled in) sites of pShuttleX (BD 
Biosciences, Palo Alto, Ca).  ￿LMP1 was generated by digesting pShuttleX-LMP1 with 
Nhe I and BsrG I, Klenow fill in and subsequent self-ligation.  From pShuttleX-LMP1/-
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the BGH poly A, was cloned into the E1/E3 deleted adenoviral backbone vector 
pAd5F35 using pI-Sce I and I-Ceu I sites
22.  The resultant plasmids were sequenced to 
confirm the sequence of LMP1 and ￿LMP1 (SEQwright, Houston, TX).  Recombinant 
adenoviruses were generated as described in the literature
23.  Plaques positive for 
LMP1 and ￿LMP1 expression by Westernblot were expanded, purified and titered by 
standard procedures
22; 23.
Vaccinia viruses
The vaccinia recombinants
24 expressing EBV latency antigens EBNA-3A, -3B and -3C 
were a gift from Elliot, Kieff, Boston, MA and the vaccinia-EGFP virus was constructed 
according to published procedures
24 using the EGFP fragment of pEGFP - C1 and the 
shuttle plasmid pSC11 (gift from Bernard Moss, Bethesda, MD).  
Peptides for Elispot and Cytotoxicity assays
The two identified LMP1 HLA-A2 restricted peptide epitopes
17 YLQQNWWTL (YLQ) and 
YLLEMLWRL (YLL) were prepared by Martin Campbell, Synthetic Antigen Laboratory, 
The University of Texas MD Anderson Cancer Center, Houston, TX.  The YLQ peptide 
is conserved between EBV strains
25.  The YLL epitope varies in between EBV strains 
and the YLL epitope is not present in the LMP1 sequence used in this study 
(YLLEILWRL; group B virus)
25.  Therefore the peptide served as a negative control and 
no activity of LMP1-specific CTL against YLL peptide was observed.
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DC were generated by the ‘adherence method’
26; 27.  Briefly, PBMC were purified by 
Ficoll (Lymphoprep, Nycomed, Oslo, Norway) gradient separation. 4-5x10
7
mononuclear cells were plated in Cell Genix media (Technologie Transfer GMBH, 
Freiburg, Germany) containing 2 mM GlutaMAX
TM-I in T-75 flasks for 2 hours. The non-
adherent cells were removed by washing with PBS and the adherent cells were cultured 
in Cell Genix/GlutaMAX
TM-I media with 800 units/ml GM-CSF (Sargramostim Leukine, 
Immunex Corp., Seattle, WA) and 1,000 units/ml IL-4 (R&D Systems, Minneapolis, MN) 
for 5 days.  IL-4 and GM-CSF were replenished on day 2 and 4. On day 5 cells were 
harvested and transduced with recombinant adenovirus.  DC were  cultured for 2 more 
days in Cell Genix/GlutaMAX
TM-I media containing 800 units/ml GM-CSF, 1,000 units/ml 
IL-4 and for maturation10 ng/ml IL-1￿, 100 ng/ml IL-6, 10ng/ml TNF-￿ (all R&D 
Systems, Minneapolis, MN) and 1µg/ml PGE2 (Sigma, St. Louis, MO)
12; 28.
CTL Generation
2x10
6 peripheral blood mononuclear cells (PBMC) per well of a 6 well plate were 
cocultured with 1x10
5 per well autologous, irradiated, Ad_￿LMP1 transduced DC 
(DC_￿LMP1) in 2 ml of complete medium (45% RPMI-1640, 45% Clicks (Irvine 
Scientific, Santa Ana, CA), 2mM GlutaMAX-1, 10% FCS).  Cultures were restimulated 
on day 10 and after that weekly with DC_￿LMP1 at a responder to stimulator ratio of 
10:1.  IL-2 (Proleukin, Chiron, Emeryville, CA), 40 units/ml, was first added with the third 
stimulation and then twice weekly.
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The  expression  of  LMP1  and  ￿LMP1  was  detected  by  FACS  analysis.  Briefly, 
transduced  DC  were  fixed  for  10  minutes  in  4%  paraformaldehyde  (PFA)  and  then 
permeablized  with  1%  saponin.    The  monoclonal  LMP1  antibody  cocktail
29,  CS1-4 
(Research  Diagnostics  Inc.,  Flanders,  NJ),  recognizing  the  common  C-terminus  of 
LMP1  and  ￿LMP1  was  used  as  primary  antibody  and  goat  anti  mouse-FITC  (BD 
Biosciences,  Palo  Alto,  Ca)  as  secondary  antibody.  Samples  were  aquired  on  a 
FACScan flow cytometer (BD Biosciences, Palo Alto, Ca) and the data were analyzed 
using CELLQuest software (BD Biosciences, Palo Alto, Ca).  Nontransduced DC served 
as negative control.  Expression of the surface molecules was measured on non-fixed, 
non-permeabilized DC using PE-conjugated monoclonal antibodies: anti-CD3, -CD14, -
CD16,  -CD19,  -CD56,  -CD80,  -CD83,  -CD86  and  anti-DR  PerCP.    CTL  lines  were 
analyzed with anti-CD8 FITC, -CD16 FITC, -TCR ￿/￿ FITC, -CD4 PE -CD56 PE, -CD16 
PE, -TCR ￿/￿ PE and anti-CD3 PerCP.  All monoclonal antiobodies were obtained from 
BD  Biosciences,  Palo  Alto,  CA  except  anti-CD16  PE,  -CD56  PE  and  -CD83  PE 
(Immunotech, Marseille, France).
Elispot Assays
The Elispot assay was performed with modifications as described in the literature
30.  A 
Multiscreen 96 well plate (Millipore, Bedford, MA) was precoated with ‘capture’ antibody 
against IFN-￿ (Mabtech AB, Nacka, Sweden) overnight at 4°C. The wells were washed 
three times with phosphate buffered saline (PBS) and then blocked with RPMI 
1640/2mM GlutaMAX
TM-I containing 10% FCS for at least 1 hour.  PBMC, EBV- and 
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GlutaMAX
TM-I containing 5% human serum (HS; C-six Diagnostic Inc., Germantown, 
WI).  Cells were set up in triplicates in a separate 96 well plate to avoid membrane 
damage of the Multiscreen plate and serial diluted; for PBMC the undiluted well 
contained 1x10
5 cells and for CTL 1x10
4 cells.  The blocking media was removed from 
the Multiscreen plate, the wells were washed twice with PBS and 100 µl of the serial 
diluted cells were transferred into each well.  100 µl of autologous, irradiated LCL (1x10
5
cells) or peptide (10
-5 M) resuspended in RPMI 1640/2mM GlutaMAX
TM-I containing 5% 
HS and 200 units/ml IL-2.  In each assay negative controls included PBMC, CTL, LCL 
or peptide alone and as positive control PBMC or CTL stimulated with 2.5 µg/ml PMA 
(Sigma, St. Louis, MO) and 1µg/ml ionomycin (Sigma, St. Louis, MO).  After 16 - 20 
hours the plates are washed 6 x with PBS/0.05% Tween 20, incubated for 2 hours with 
biotinylated ‘detection’ antibody against IFN-￿ (Mabtech AB, Nacka, Sweden).  The 
plates were washed 6 x with PBS/0.05% Tween 20. 100 µl of Avidin-Peroxidase-
Complex (AEC; prepared according to manufacturer instructions; Vector Laboratories, 
Burlingame, CA) was added per well for 1 hour at room temperature.  The plates were 
washed 3x with PBS/0.05% Tween 20, followed by 3x washes with plain PBS.  AEC 
substrate (Sigma, St. Louis, MO) was prepared by dissolving one AEC tablet in 2.5 ml 
Dimethylformamide, adding 47.5 ml of sodium acetate buffer and 25 µl of 30% 
Hydrogen Peroxide.  Prior to use the AEC substrate was filtered through a 0.45 µM filter 
and 100 µl was added per well.  After 4 minutes the reaction was stopped by washing 
with deionized water and the plates were dried overnight prior membrane removal.  The
spot number was determined in an independent blinded fashion (ZellNet Consulting, 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From Inc., NY, NY) using a high-resolution automated Elispot Reader System (Carl Zeiss, 
Inc., Thornwood, NY) using KS Elispot 4.3 software.  In all assays the background was 
less than five spot forming cells (SFC)/10,000 cells.  Linear regression analysis and 
statistical analysis (Wilcoxon Signed-Rank test) was performed using GB-STAT 
(Dynamic Microsystems Inc., Silver Spring, MD).  
Cytotoxicity Assays
The CTL were tested for specific cytotoxicity against autologous fibroblasts either 
uninfected or infected with recombinant adenovirus or vaccinia virus constructs.  
Fibroblasts were exposed to 100 units/ml IFN-￿ (R&D Systems, Minneapolis, MN) 24 -
48 hours prior to the cytotoxicity assay and infected on the day of the cytotoxicity assay 
with vaccinia virus recombinants containing EBNA-3A, -3B, -3C and -EGFP or 24 hours 
before with adenovirus recombinants containing an empty expression cassette, LMP1 
￿LMP1.  Recombinant vaccinia virus expressing LMP1 could not be used due to the 
additive toxicity of LMP1 and vaccinia virus infection.  Autologous LCL, HLA class I 
mismatched LCL and autologous PHA blasts were also tested.  Where indicated PHA 
blasts were loaded with peptide for 1 hour after 
51Chromium (
51Cr) labeling.  1x10
6
target cells were labeled with 0.1 mCi 
51Cr and mixed with various numbers of effector 
cells to give effector:target ratios of 40:1, 20:1, 10:1 and 5:1.  Target cells incubated in 
complete medium alone or in 1%Triton X-100 were used to determine spontaneous and 
maximum 
51Cr release, respectively. After 4 hours (LCL, PHA blasts) or 5 hours 
(fibroblasts) supernatants were collected and radioactivity was measured on a gamma 
counter. The mean percentage of specific lysis of triplicate wells was calculated as 100x 
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release).
Western blot
Lysates of LCL and fibroblasts were prepared by washing cells 1x with ice cold PBS 
and boiling samples for 5 minutes in Laemmli buffer (Pierce Biotechnology, Inc., 
Rockford, IL).  Fibroblasts were transduced with Ad_LMP1 or Ad_￿LMP1 24 hours prior 
harvest as for cytotoxicity assays.  Non-transduced fibroblasts served as negative 
control.  Samples were separated by sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) 
membranes (Pall Life Science, Ann Arbor, MI).  Membranes were blocked in Tris-
buffered saline containing 0.1% Tween 20 (TBS-T) and 5% milk powder (MP).  
Membranes were washed 2x with TBS-T and incubated for 1 hour with anti-LMP1 
antibody CS1-4 in TBS-T containing 2% MP.  Membranes were washed 4x with TBS-T 
and incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody 
(Amersham Biosciences Corp, Piscataway, NJ) for 1 ½ hours in TBS-T containing 1% 
MP.  The membrane was washed 4x with TBS-T and bound HRP was detected by 
enhanced chemiluminescence (ECL Plus
TM; Amersham Biosciences Corp, Piscataway, 
NJ).
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LMP1 expression is toxic in dendritic cells
Different adenoviral vectors have been tested for their efficiency in transducing human 
DC
31.  The most efficient vector identified has a serotype 5 capsid containing the short 
shafted fiber protein of serotype 35 (Ad5F35).  Recombinant Ad5F35 vectors containing 
LMP1 and ￿LMP1 were generated according to Yotnda et al .
22 and the resultant 
constructs are shown in Figure 1.  To evaluate the effect of LMP1 and ￿LMP1 
expression, DC were transduced with increasing MOI of Ad_LMP1 and Ad_￿LMP1.  48 
hours after transduction the number of viable and LMP1 positive cells were determined 
by FACS analysis.  32% of DC were positive for LMP1 expression after transduction 
with Ad_LMP1 at a MOI of 3.  Higher MOIs led to no significant increase in transduction 
efficiency, but resulted in greater than 60% cell death (Figure 2).  In contrast, greater 
than 80% of DC were positive for ￿LMP1 at all MOIs tested.  There was an adenoviral 
dose dependent decrease in DC viability, but 90% of DC were viable at a MOI of 3, 
indicating that high levels of ￿LMP1 expression could be achieved with minimal toxicity 
(Figure 2).  The marked cytopathic effects of LMP1 expression in DC prevented the 
further use of Ad_LMP1 transduced DC for CTL generation.  
￿ ￿￿￿LMP1 is functionally inactive in dendritic cells
To confirm that ￿LMP1 was functionally inactive in DC we measured their production of 
TNF-￿ and IL-10, two cytokines that are known to be induced by LMP1
32.  Immature DC 
were transduced with Ad_EGFP, Ad_LMP1 and Ad_￿LMP1 and 48 hours after 
transduction the concentration of the two cytokines were determined by FACS using the 
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TNF-￿ and IL-10, while ￿LMP1 and EGFP expressing DC did not, indicating that 
￿LMP1 is functionally inactive (Figure 3A).  
The ￿LMP1 transduced DC were further characterized to demonstrate that ￿LMP1 
expression had no effect on DC maturation.  Immature DC were transduced on day 5 
with Ad_￿LMP1 at a MOI of 6 and cultured for 2 more days in the presence of a 
cytokine cocktail containing IL-4 and GM-CSF and for maturation TNF-￿, IL-1￿, IL-6 and 
PGE-2.  DC were analyzed by FACS for DR (bright), CD83 and ￿LMP1 expression and 
the result of 15 DC preparations from three donors is shown.  97% of transduced DC 
were positive for ￿LMP1 and expression of DR and CD83 was unchanged compared 
with controls (Figure 3B), indicating that Ad_￿LMP1 leads to high levels of ￿LMP1 
expression without changing the DC phenotype.
CTL generated with ￿ ￿￿￿LMP1 expressing DC recognize an HLA-A2 restricted LMP1 
peptide epitope
LMP1-specific CTL were generated from three healthy, HLA-A2, EBV - seropositive 
donors by stimulating PBMC with autologous DC expressing ￿LMP1 (DC_￿LMP1).  The 
phenotype of DC_￿LMP1 induced CTL was similar for all three donors with greater than 
95% being CD3 positive.  More than 80% of the CD3 positive T cells were positive for 
CD8, 11-20 % for CD4 and greater than 95% were TCR ￿￿ positive.  Less than 5% of 
cells were positive for natural killer cell markers (CD3 negative and CD56 positive).  
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specific CTL, IFN-￿ Elispot assays were performed using the HLA-A2 restricted LMP1 
peptide epitope YLQQNWWTL (YLQ).  This epitope is located between the 5
th and 6
th
transmembrane domain of LMP1 (Figure 1) and is conserved in between the laboratory 
EBV strain B95-8, European and Chinese EBV isolates
25.  Depending on the donor, 0.5 
– 3.8% of the CTL secreted IFN-￿ in response to YLQ peptide, demonstrating that the 
generated CTL had specificity for this particular HLA-A2 restricted LMP1 epitope (Figure 
4). No YLQ-specific CTL were observed when PBMC of donor B were stimulated with 
untransduced dendritic cells (data not shown).  
The frequency of YLQ-specific CTL was less than 0.01% (undetectable) in EBV-specific 
CTL generated using EBV-transformed lymphoblastoid cell lines (LCL) as antigen 
presenting cell lines (APC), indicating that only DC_￿LMP1 direct the stimulation of 
LMP1-specific CTL (Figure 4).  To estimate the expansion of YLQ-specific CTL after 
DC_￿LMP1 stimulation, their frequency was determined in PBMC.  The frequency in all 
three donors was below the detection limit of the Elispot assay (0.001%), indicating that 
the frequency of YLQ-specific CTL had increased at least 500 - 3,800 x fold after 4 - 6 
stimulations (30 - 50 days; Figure 4).  
LMP1-specific CTL recognize LCL
Having established that the DC_￿LMP1 activated CTL recognize the LMP1 derived 
YLQ-peptide epitope, it was important to determine if the generated CTL recognize 
autologous LCL, in which LMP1 is naturally expressed by EBV.  Depending on the 
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(Figure 5) in contrast to less than 0.7% in PBMC prior stimulation.  The frequency of 
CTL recognizing LCL in EBV-specific CTL lines for all three donors was 38-49% (data 
not shown).
Cytotoxic Activity of LMP1-specific CTL
To determine if the generated LMP1-specific CTL not only secreted IFN-￿ after YLQ 
peptide or LCL stimulation, but also had cytotoxic activity, CTL were tested against a 
panel of targets in cytotoxicity assays.  LMP1-specific CTL lysed autologous PHA blast 
loaded with YLQ-peptide, whereas PHA blasts alone or with an unrelated HLA-A2 
restricted peptide were resistant to killing (Figure 6A).  In addition, LMP1-specific CTL 
lysed autologous fibroblasts expressing LMP1 and ￿LMP1 from the adenoviral vector 
(Figure 6B).  No lysis of targets transduced with an adenovirus without a transgene was 
observed, indicating that the stimulation protocol did not lead to the expansion of 
adenovirus-specific CTL.  LMP1-specific CTL of all three donors were tested for their 
ability to lyse autologous LCL in which LMP1 is solely expressed by EBV.  Only CTL 
from donor A, who had the highest frequency of reactive CTL against YLQ peptide and 
LCL, lysed autologous LCL (Figure 6C).  Decreased susceptibility to CTL lysis might be 
explained either by sequence variation of LMP1, differences in the level of LMP1 
expression in fibroblasts and LCL or by the low frequency and/or affinity of LMP1-
specific CTL
30; 33; 34.  The LMP1 sequence of B95 - 8 EBV used to generate LCL is almost 
identical (99.1% homology) to the LMP1 used for CTL generation, excluding epitope 
variation that would result in LCL resistance to CTL lysis.  The level of LMP1 and
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LCL (Figure 7), indicating that the lysis of target cells depends on the level of antigen 
expression.  Thus the frequency and/or affinity of LMP1-specific CTL in donor B and C 
only allows for killing of targets, which express LMP1 at higher levels than LCL.  In an 
attempt to increase the frequency and/or affinity of LMP1-specific CTL for donor B we
combined initial DC_￿LMP1 stimulations with subsequent autologous LCL stimulations.  
The resultant LMP1-specific CTL line had a 2-fold higher frequency of YLQ-specific CTL 
in comparison to stimulations with DC_￿LMP1 alone (Figure 8).  In addition killing of 
autologous fibroblast expressing ￿LMP1 as well as autologous LCL was observed 
(Figure 9A).  To exclude that stimulation with LCL after initial DC_￿LMP1 stimulations 
led to an expansion of CTL recognizing immunodominant EBV proteins, cytoxicity 
assays were performed using autologous fibroblast expressing EBNA-3A, -3B and -3C.  
No lysis of targets was observed, in contrast to LCL activated EBV-specific CTL, which 
killed EBNA-3B and -3C expressing targets (Figure 9A and 9B).  Moreover, EBV-
specific CTL did not lyse LMP1 expressing targets confirming the Elispot assay results 
that only DC_￿LMP1 and not LCL direct the expansion of LMP1-specific CTL (Figure 
9B).
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We demonstrate that human DC, expressing functionally inactive LMP1, efficiently 
activate and expand LMP1-specific CTL from PBMC of healthy, HLA-A2, EBV-
seropositive donors.  Polyclonal LMP1-specific CTL lines recognized a HLA-A2 
restricted LMP1 peptide, YLQ, and lysed target cells expressing wildtype LMP1 in 
cytotoxicity assays.  In contrast, expression of wildtype LMP1 was toxic in DC 
preventing CTL generation and no LMP1-specific CTL were detected in LCL activated 
EBV-specific CTL, indicating that only DC_￿LMP1 can direct the activation and 
expansion of LMP1-specific CTL.
Different methods have been developed to deliver antigens to DC for CTL activation 
and expansion such as 1) loading with peptides, proteins or tumor cell lysate, 2) fusion 
of DC with tumor cells, and 3) gene transfer with DNA, RNA or recombinant viral 
vectors
35; 36.  Genetic modification of DC offers several advantages including persistent 
expression of full-length antigen allowing for the presentation of multiple/undefined 
epitopes and the ability to genetically modify antigens to make them more potent or - as 
for LMP1 - less toxic.  For clinical applications recombinant adenoviruses are attractive 
vectors for the genetic modification of DC, since high transduction rates are achieved 
without interfering with DC function in comparison to other viral vectors, like vaccinia 
virus or herpes simplex virus
37; 38.  Adenoviral transduced DC have been used 
successfully in vitro to generate specific CTL against a variety of tumor associated 
antigens
10; 39; 40.  In addition these vectors can be produced in high titers under current 
good manufacturing conditions and in phase I clinical trials their safety record has been 
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expansion is the generation of low affinity/avidity T cell
41; this has not been observed 
with adenoviral vectors but may occur with other viral vectors, like vaccinia virus, which 
are capable of expressing antigens at much higher levels.
To separate the functional properties of LMP1 from its potential epitopes for antigen 
presentation we constructed recombinant adenoviral vectors expressing LMP1 or 
￿LMP1, a functionally inactive LMP1.   ￿LMP1 is not only inactive and nontoxic but also 
lacks its first transmembrane domain, which shares homology with the retroviral 
immunosuppressive domain p15a
42; 43.  Peptides derived from this domain inhibit T-cell 
proliferation and since LMP1 fragments can be detected in the supernatant of LMP1 
expressing cells, LMP1 might have a direct immunosuppressive effect on T cells. High 
levels of ￿LMP1 expression with little toxicity were achieved in DC and ￿LMP1 did not 
induce cytokines like TNF-￿ or IL-10.  In contrast LMP1 expression was toxic in human 
DC preventing our planned investigation of how LMP1 expression in DC affects their 
ability to activate and stimulate T cells.  However, the observed induction of IL-10 is an 
indication that expression of LMP1 may impair DC function, since IL-10 down regulates 
HLA-class II expression and inhibits their activation of TH1 immune responses 
44.  
Further studies are needed to establish how LMP1 modulates the cellular immune 
response since other investigators have observed potential immunosuppressive as well 
as stimulatory effects
42; 45; 46. 
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considered advantageous for adoptive immunotherapy protocols, since infused CD8 T 
cells do not persist long term without the presence of CD4 cells
19.  The specificity of the 
generated CD4 T cells has not been determined and the identification of MHC class II 
restricted epitopes is in progress.  Of the expanded CTL 0.5% - 3.8% recognized the 
HLA-A2 restricted LMP1 epitope YLQ.  In polyclonal EBV-specific CTL lines, 
frequencies between 6-8% have been reported for single EBNA-3A and -3C epitopes
47
using tetramer analysis and in LMP2-specific CTL lines up to 20% of cells may bind to a 
tetramer of a single LMP2 epitope
10.  Most likely, these differences are a function of the 
CTL precursor frequency in PBMC for a specific antigen and the frequency for LMP1 
epitopes is lower than for EBNA-3A, -3C and LMP2 epitopes
5.  Indeed, we were not 
able to detect YLQ-specific CTL in PBMC of any of the three donors.  In addition, IFN-￿
Elispot assays are likely to underestimate the frequency of epitope-specific T cells in 
comparison to tetramer analysis, since only 30-80% of tetramer positive T-cells secrete 
IFN-￿ after specific stimulation
48; 49.  The remainder of the LMP1-specific CTL were 
either specific for other undefined LMP1 epitopes or were produced as a result of 
nonspecific CTL stimulation.  The only other HLA-A2 restricted LMP1 epitope, 
YLLEMLWRL (YLM), currently identified
17, was not present in the LMP1 sequence used 
in these experiments and studies are currently in progress to identify novel LMP1-
specific CTL epitopes.  
If LMP1-specific CTL are to be of therapeutic benefit, they must recognize LMP1 
expressed at physiological levels from its natural promoter.  Therefore, we determined 
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LCL-reactive CTL in IFN-￿ Elispot assays was 2% - 8.5%, establishing that LMP1-
specific CTL recognize LCL.  In EBV-specific CTL generated by LCL stimulation from all 
three donors, the frequency of LCL-specific CTL was 38% - 49%, indicating that LMP1-
specific CTL lines contain a higher percentage of CTL that were of low affinity, had 
activities other than IFN-￿ secretion, or were nonspecific. 
LMP1-specific CTL lines killed PHA blasts loaded with YLQ - peptide, and autologous 
fibroblasts expressing wildtype LMP1 or ￿LMP1.  The killing of fibroblasts expressing 
LMP1 was lower than of fibroblasts expressing ￿LMP1, because LMP1 expression in 
fibroblasts as in DC was toxic and lower levels of gene expression were achieved in 
comparison to ￿LMP1.  Only CTL from donor A, who had the highest frequency of 
reactive CTL against the LMP1 derived YLQ peptide and LCL in Elispot assays, lysed 
autologous LCL, which expressed LMP1 at a lower level than fibroblasts transduced 
with Ad_LMP1 or Ad_￿LMP1.  This finding is consistent with previous published results 
that lysis of target cells is dependent on the level of antigen expression and the 
frequency and/or affinity of antigen-specific CTL
30; 33; 34.  Thus the frequency and/or 
affinity of LMP1-specific CTL in donor B and C only allows killing of targets, which 
express LMP1 at higher levels than LCL.  However, the level of LMP1 expression in 
LCL is lower than in malignant H-RS cells of EBV-positive Hodgkin’s disease
50; 51.  
Therefore it would be of great interest to test the ability of LMP1-specific CTL to lyse 
EBV-positive H-RS cell lines, but no cell line is readily available for such studies.  In an 
effort to increase the frequency and/or affinity of LMP1-specific CTL in the generated T-
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LMP1-specific CTL line lysed ￿LMP1 expressing fibroblast and autologous LCL; no 
killing of targets was observed expressing the immunodominant EBV proteins 
recognized by LCL activated EBV-specific CTL from the same donor.  Other 
investigators have used the sequential combinations of APC to generate antigen-
specific T cells
17; 18; 52; most likely nonspecific T cell proliferation is reduced and/or the 
affinity of the generated antigen-specific T cells is increased since the level of antigen 
expression varies between different APC.  Moreover, for the ex vivo generation of 
LMP1-specific CTL for adoptive immunotherapy protocols the use of LCL to expand 
DC_￿LMP1-activated CTL is advantageous since it decreases the patient’s blood 
volume required for DC generation.  The efficacy of LMP1-specific T cells therapy for 
the adoptive immunotherapy of EBV-positive Hodgkin’s disease may be determined 
only in a clinical trial.  So far we have only generated LMP1-specific CTL from healthy 
donors.  In the past we have shown that EBV-specific CTL can be generated from 
patients with EBV-positive Hodgkin’s disease; the expansion of EBV-specific CTL was 
found to be ~10-fold lower than in healthy donors and the generation of sufficient 
numbers of CTL for infusion required the use of a mitogenic cocktail
1; 4.  These results 
indicate, that the generation of LMP1-specific CTL from patients with Hodgkin’s disease 
should be feasible. 
No adenoviral-specific killing was observed in the present study.  This findings is in 
accordance with results of other investigators using similar DC based CTL stimulation 
protocol
10; 12; 39; 40.  The absence of adenovirus-specific CTL may be protocol specific 
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to allows for maturation and transgene expressions.  This most likely results in loss of 
adenoviral-derived epitopes, since adenoviral-specific CTL could be re-activated when 
DC were cultured with PBMC immediately after adenoviral transduction
53.
In summary, we described the generation of LMP1-specific CTL for future adoptive 
immunotherapy protocols for patients with LMP1-positive malignancies, like EBV-
positive Hodgkin’s disease or nasopharyngeal carcinoma.  The generation of LMP1-
specific CTL was possible only using an inactive, non-toxic LMP1 mutant.  The strategy 
of rendering a protein inactive to allow antigen presentation may be applicable to other 
tumor associated antigens, which are cytotoxic, immunosuppressive or oncogenic in 
their native form.
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Figure 1: Structure of LMP1 and ￿ ￿￿￿LMP1.  LMP1 consists of a short N-terminus, 6 
transmembrane domains and two C-terminal activation regions. The first 
transmembrane domain is homologous to the retroviral transmembrane domain p15a. * 
indicates the position of the HLA-A2 restricted YLQQNWWTL peptide used in this study. 
￿LMP1 lacks the N-terminus and the first transmembrane domain.
Figure 2: LMP1 expression is toxic in dendritic cells.  Day 5 immature DC were 
transduced with increasing MOI of Ad_LMP1 and Ad_￿LMP1.  After transduction the 
DC were matured with a cytokine cocktail for 2 days.  (A) LMP1 expression and (B) the 
percentage of viable large cells were determined by FACS analysis.  The transduction 
efficiency of Ad_LMP1 was lower than Ad_￿LMP1 and LMP1 expression was toxic 
Figure 3: ￿ ￿￿￿LMP1 is functionally inactive in dendritic cells.  (A) Day 5 immature DC 
were transduced with Ad_EGFP, Ad_￿LMP1, and Ad_LMP1 at a MOI of 3.  After 48 
hours cell free media was collected and the concentration of TNF-￿ and IL-10 was 
determined by FACS using the Cytokine Cytometric Bead Array kit (BD Biosciences, 
Palo Alto, Ca).  Only LMP1 induced high levels of TNF-￿ and IL-10.  (B) Day 5 
immature DC were transduced at a MOI of 6 and matured with a cytokine cocktail for 2 
days prior to FACS analysis for DR, CD83 and ￿LMP1 expression (donor A, B and C; 
n=15).  ￿LMP1 expression did not affect the expression of DR and CD83 in comparison 
to non-transduced DC (control).
Figure 4: LMP1-specific CTL lines recognize the HLA-A2 restricted LMP1 epitope 
YLQQNWWTL (YLQ).  The ability of T cells in PBMC, EBV-specific CTL and LMP1-
specific CTL to secrete IFN-￿ in response to the LMP1 peptide YLQ was determined in 
Elispot assays.  Spot forming cells (SFC) were quantified by Zellnet Consulting, Inc., 
New York, NY.  No reactive cells were observed in PBMC and EBV-specific CTL for all 
three donors.  The frequency of YLQ-peptide reactive LMP1-specific CTL was 3.82% for 
donor A, 0.52% for donor B and 0.55% for donor C.  YLQ-peptide reactive CTL were 
undetectable in PBMC and EBV-specific CTL.
Figure 5: LMP1-specific CTL lines recognize autologous LCL.  The ability of T cells 
in PBMC, EBV-specific CTL and LMP1-specific CTL to secrete IFN-￿ in response to 
autologous LCL was determined in Elispot assays. Spot forming cells (SFC) were 
quantified by Zellnet Consulting, Inc., New York, NY.  The frequency of LCL reactive 
CTL in LMP1-specific CTL was 8.5% for donor A, 2.0% for donor B and 4.6% for donor 
C and in PBMC, 0.34%, 0.57% and 0.68% respectively.
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were tested for their ability to lyse autologous targets.  (A) Autologous PHA blasts of 
donor A and C loaded with YLQ-peptide were killed in cytotoxicity assays by LMP1-
specific CTL at a effector:target ratio of 40:1.  PHA blast alone, or loaded with a control 
peptide (YLL) were not lysed.  (B) Autologous fibroblasts of donor B expressing LMP1 
and ￿LMP1 were killed by LMP1-specific CTL.  Non-transduced fibroblasts and 
fibroblasts transduced with an adenoviral vector without transgene were not lysed.  (C) 
LMP1-specific CTL of donor A killed autologous LCL.  No cytotoxic activity was 
observed against mismatched targets. 
Figure 7: LMP1 expression in Fibroblasts and LCL.  Fibroblasts were harvested 24 
hours after transduction with Ad_LMP1 and Ad_DLMP1. 2x10
3 cells/lane of fibroblasts 
and 2x10
5 cells/lane of LCL were loaded.  LMP1 expression was detected by western 
blot using the monoclonal antibody cocktail CS1-4 and HRP-conjugated secondary 
antibodies.  LMP1 expression was detected in transduced fibroblasts as well as LCL 
and the level of LMP1 expression was higher in fibroblasts than in LCL.  Protein 
standards are indicated at the left in kilo Daltons (*: cross reactive band only present in 
fibroblasts).
Figure 8: LMP1-specific CTL generated by initial DC_￿ ￿￿￿LMP1 stimulations followed 
by autologous LCL stimulations recognize the HLA-A2 restricted LMP1 epitope 
YLQQNWWTL (YLQ). The ability of LMP1-specific CTL generated by DC_￿LMP1 
stimulations followed by autologous LCL stimulations to secrete IFN-￿ in response to the 
LMP1 peptide YLQ was determined in Elispot assays.  Spot forming cells (SFC) were 
quantified by Zellnet Consulting, Inc., New York, NY.  The frequency of YLQ reactive 
CTL was 0.9% in contrast to 0.52% for LMP1-specific CTL, which were only stimulated 
with DC_￿LMP1 (p < 0.001; Wilcoxon signed-rank test) 
Figure 9: Cytotoxic activity profile of LMP1 - and EBV-specific CTL.  (A) LMP1-
specific CTL were generated by DC_￿LMP1 stimulations followed by autologous LCL 
stimulations and (B) EBV-specific CTL by LCL stimulations alone.  Both were tested at a 
effector:target ratio of 40:1 against a panel of autologous targets, including autologous 
LCL (LCL), mismatched LCL (MM), fibroblasts alone (-), fibroblasts infected with 
recombinant vaccinia virus expressing EGFP, EBNA-3A, -3B, or -3C, or fibroblasts 
infected with recombinant adenovirus without transgene (Ad) or ￿LMP1.  Both CTL lines 
killed autologous LCL, however only LMP1-specific CTL killed LMP1 expressing targets.  
No cytotoxic activity of LMP1-specific CTL was observed against EBNA-3B and -3C 
expressing targets in contrast to EBV-specific CTL.
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